Chymotrypsinogen/trypsinogen - Propanc

Drug Profile

Chymotrypsinogen/trypsinogen - Propanc

Alternative Names: PRP; PRP-DCP; PRP-Injection

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Propanc Health Group Corporation
  • Developer Propanc Biopharma
  • Class Antineoplastics; Enzyme precursors; Serine endopeptidases
  • Mechanism of Action PAR-2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Cancer
  • Preclinical Colorectal cancer; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 28 Dec 2017 Propanc Biopharma plans first-in-human trial for Solid tumours (Late-stage disease) in United Kingdom in early 2018
  • 04 Dec 2017 Propanc announces intention to submit Clinical Trial Application for first-in-human study in Solid tumours in United Kingdom in the first half of 2018
  • 04 Dec 2017 Propanc Biopharma plans a proof-of- concept phase II trial for Ovarian cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top